As of 6 January, the likelihood of approval (LoA) for Beijing Sunbio Biotech’s Phase III drug for relapsed and refractory multiple myeloma rose 18–19 points, according to GlobalData’s LoA data.
The score change was based on results provided during the American Society of Hematology (ASH) annual meeting held last December.
Go deeper with GlobalData
On 6 December 2020, the company showcased Phase III relapsed or refractory multiple myeloma trial results, noting that circularly permuted TRAIL (CPT) was an effective drug when combined with thalidomide and dexamethasone (TD), including among patients who had previously received multiple lines of treatment, and those who were refractory to proteasome inhibitors (PI) and immunomodulators (IMIDs).
CPT, a recombinant permuted human TNF-related apoptosis-inducing ligand (TRAIL), targets death receptor 4/5.
LoA up, but no disclosure on US New Drug Application intention
While the LoA by the FDA prior to this news was 25–26%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has notched up the LoA to 43–45%. The company has not disclosed whether it intends to file a US NDA.
According to the paper published on the ASH website, out of 415 patients in the trial, 276 received CPT/TD and 139 were in the TD-alone arm; the median number of lines of previous treatment was three; and PI and IMID were previously used in 74% and 86.5% of patients, respectively.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAt data cutoff, the primary endpoint of media progression-free survival was 5.5 versus 3.1 months in the treatment and comparator groups, respectively (hazard ratio 0.619; p < 0.0001). Key secondary endpoints of overall response rate (30.4% versus 13.7%, p = 0.0002) and median overall survival (21.8 versus 17.0 months; HR 0.723; p = 0.0166) were also improved.
